It moves the conversation from guessing about symptoms to developing a precise, evidence-based treatment plan tailored to your body's unique hormonal landscape. Normal levels of FSH, LH, and testosterone suggest the HPG axis is functioning correctly. Consequently, both testosterone and gonadotropin levels are low. Testosterone binds strongly to SHBG, and it is therefore largely the free and albumin-bound testosterone that is available for biological action (10). Secretion of LH from the pituitary is not constant, but has approximately six bursts of secretion per day with an early morning high and an early evening low. FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone LH acts on the interstitial Leydig cells of the testes, stimulating them to produce testosterone, whereas FSH stimulates spermatogenesis and Sertoli cell function (6,7). The regulation of testosterone production in eugonadal men depends on the HPG axis depicted in Figure 1. The different names have arisen as authors try to separate the hypogonadism resulting from natural ageing from, for example, the hypogonadism caused by testicular trauma. The Androgen Deficiency in Ageing Males (ADAM) questionnaire can be helpful to initiate a conversation about the symptoms they may be experiencing (75) (Table 6). HIV patients with AIDS are younger and therefore, comparisons have to be carried out with appropriately age-matched controls. Approximately 20–50% of HIV-infected men receiving highly active antiretroviral therapy are hypogonadal. The mechanism for OPIAD is thought to involve suppression of GnRH release by the hypothalamus, thereby inducing secondary hypogonadism (17,70). Long-acting opioids such as methadone, morphine sulphate, fentanyl and oxycodone for the treatment of chronic pain often result in opioid-induced androgen deficiency (OPIAD). Systemic glucocorticoids can reduce testosterone biosynthesis in the testis; in addition, glucocorticoids impact the HPG axis by inhibiting the release of LH (17,68). In a study of elderly men in a nursing home who have experienced hip fractures, 66% were hypogonadal (64). It is important to consider treating symptomatic patients and not leave them untreated because of anxiety over possible adverse events from testosterone replacement therapy, after discussing with them the potential benefits and risks of treatment. The Institute of Medicine has suggested that to assess a moderate increase in the risk of prostate cancer from testosterone treatment, a large trial requiring 5000 men followed over 3–5 years would be needed (95). Likewise, studies have shown that there is no significant difference between testosterone levels in men with or without prostate cancer (89,92). However, the increase in size of the prostate needs to carefully monitored, and the patient needs to be made aware that there might be increased voiding symptoms during treatment (2,4,9,79,89). Studies with hypogonadal men have demonstrated that once testosterone levels are restored to a stable normal range, there is an improvement in libido, sexual function, mood and energy levels relatively early in the course of treatment (78,84–86). A brief discussion on the physiology of testosterone production can be found in Appendix 1, online supplementary evidence. Accordingly, for early onset, such as that occurring during foetal life, the clinical phenotype can span from an almost complete female phenotype (e.g. complete androgen insensitivity or enzymatic defects blocking androgen synthesis) to various defects in virilisation. The current Guidelines maintain a classification of primary and secondary hypogonadism, with special reference to LOH. Male hypogonadism can be classified according to the aetiology into primary hypogonadism or secondary hypogonadism (Table 3.1) 3,17. In men aged years, the incidence of symptomatic hypogonadism varies between 2.1 and 5.7% 6,8,9. The incidence of hypogonadism has been reported to be between 12.3 and 11.7 cases per 1,000 people per year 6,7. "Normal" ranges for testosterone also vary significantly based on your age and sex. In most cases, you should get the results of your testosterone test within two to three business days, though it could take longer. The entire procedure (blood draw) for a testosterone test usually takes less than five minutes. High levels may point to precocious (early) puberty. Free testosterone is easier for your body to use. A testosterone level that’s too low or high can cause health problems regardless of your sex. Your body functions best when your testosterone is in a certain range. When testosterone levels are low, gonadotropin-releasing hormone (GnRH) is released by the hypothalamus, which in turn stimulates the pituitary gland to release FSH and LH. Studies have shown small or inconsistent correlations between testosterone levels and male orgasm experience, as well as sexual assertiveness in both sexes. This is known as hormone replacement therapy (HRT) or testosterone replacement therapy (TRT), which maintains serum testosterone levels in the normal range. For women with PCOS, hormones like birth control pills can be used to help lessen the effects of this increased level of testosterone. Similarly, Behre et al.22 demonstrated increased prostate volume and prostate-specific antigen (PSA) levels in hypogonadal men to those seen in aged-matched normal men after treatment with TRT. In the late-onset hypogonadal male, the addition of testosterone (even to return levels to a "normal" range) was hypothesized by extrapolation to increase prostatic size and thus worsened of LUTS secondary to BOO. While Favilla et al.15 were able to demonstrate an association between LUTS and serum levels of total testosterone in the study of 122 men with symptomatic BPH, they did not find a similar association with BPH/BPE and testosterone. However, Marks et al.14 recently disputed this concept when finding no evidence of increased intra-prostatic DHT with testosterone replacement therapy (TRT) in a small, randomized control trial (RCT). Urologists have known of testosterone's importance in prostate development and pathology for some time, but only more recently have we begun to better understand its effects on lower urinary tract symptoms (LUTS); and more importantly, that these symptoms are not always entirely due to bladder outlet obstruction (BOO). Surprisingly, numerous retrospective or small, randomized trials have pointed to a possible improvement in male lower urinary tract symptoms (LUTS) in patients treated with testosterone. The use of testosterone to treat the symptoms of late-onset hypogonadal men has increased recently due to patient and physician awareness. However, the concentrations of testosterone required for binding the receptor are far above even total circulating concentrations of testosterone in adult males (which range between 10 and 35 nM). Fairer offers from test subjects with higher testosterone in the original study increase the likeliness of the offer being accepted by the negotiating partner, therefore decreasing the probability of both participants leaving without any money. A few studies indicate that the testosterone derivative estradiol might play an important role in male aggression. The Annals of the New York Academy of Sciences has found that the use of anabolic steroids (which increases testosterone) among teenagers is correlated with increased likelihood of using violence. In one experiment, subjects who interacted with handguns showed higher testosterone levels and aggression than those who interacted with toys. The masculinization of the brain is not just mediated by testosterone levels at the adult stage, but also testosterone exposure in the womb.